Audit: QRS - R-Lipoic Acid for Health & Longevity

Audit conducted on 10/08/2026 08:09 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	91
Passed	81
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to ER text: at-a-glance to Conclusion (ER 584–586), protocol cells to Therapeutic Protocol (ER 445–457) and Risk Mitigation Strategies (ER 424, 426), time-to-effect to Practical Considerations (ER 502) and Monitoring Protocol & Defining Success (ER 562), benefits/risks to the respective tier headings, gates to ER 401–419, monitoring table to ER 530–542, qualitative items to ER 546–560.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“Nearly all testing used the blended form” mirrors ER 586; “theoretical chelation-driven mineral depletion” (marker_11_why) and “reported interference with thyroid function” (marker_7_why) carry the ER’s hedges verbatim.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications are carried at ER strength (ER 419); “no additional efficacy but more adverse events at 1,200 and 1,800 mg/day” is preserved in action_3_sub without escalation or dilution.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Benefit- and Risk-Modifying Factors (ER 288–304, 384–396) are not surfaced anywhere; gates draw only from Key Interactions & Contraindications, risks only from Potential Risks & Side Effects.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, expert names, NCT identifiers, or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, evidence-weighted register matching the ER; e.g. “the two have never been compared head to head” (action_1_sub) echoes ER 447.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Numeric targets and time windows throughout, with plain-language framing in the at-a-glance block.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated descriptively (“Single morning dosing is what the outcome data support”), not issued as instruction.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative clinical instruction in any populated span; the footer disclaimer is fixed template text.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, “should”, or equivalent in the QRS’s own voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms appear only where they are decision-load-bearing (HLA-DRB1 alleles, eGFR, albumin-to-creatinine ratio), matching ER usage.
2.8	Information is presented in a concise and very compact manner	🟢	Gate and tier items are noun phrases; monitoring “Why” cells are single clauses.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no “you”/”your” in the document.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	An 11-marker monitoring panel with functional (not conventional) reference ranges and a genotype-based contraindication list target exactly this reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Fasted morning dosing, two-week titration, and a front-loaded lab cadence are presented without hedging for convenience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Functional targets (fasting insulin 2–5 µIU/mL, hs-CRP < 0.5 mg/L) sit well inside conventional reference ranges.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	“mainly where starting values are abnormal” (at_a_glance) carries the ER’s central responder/non-responder distinction forward.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No occurrence of “anti-aging” or “antiaging”; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Gastrointestinal intolerance”, “hypoglycaemia”, “proteinuria”, “adverse events” used throughout; no consumer-grade substitutes.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All verified verbatim: lines 446, 492, 543, 619, 647, 809 (headings); 575, 591 (gates); 546/550/556/564 and 622/626/632/637 (tiers); 651–653 (table headers).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	75 data-qrs-var spans present and complete: page_title, header_topic, header_subline_date, header_subline_model, at_a_glance, action_1–3 (label/value/sub), time_1–3 (label/value/sub), benefits_high/medium/low/speculative, stop_items, caution_items, risks_high/medium/low/speculative, marker_1–11 (name/target/why), monitoring_cadence, qualitative_item_1–8.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The non-variable website="evidence_review", website="audit", and website="full_review" spans (lines 423, 426, 440) are untouched, as are the stylesheet block and the override link.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty; every benefit and risk tier, both gate lists, the protocol, the monitoring table, and the qualitative list are populated in the ER.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	All eight qualitative items reuse the ER’s bold labels verbatim (“Neuropathic symptoms”, “Energy and exercise tolerance”, “Appetite and satiety”, “Cognitive clarity”, “Gastrointestinal tolerance”, “Sleep quality and timing of any disturbance”, “Skin”, “Urine odour”); monitoring row labels match the ER table verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Benefit and risk tier items reproduce the ER sub-headings; interaction labels reproduce the ER bullet labels ahead of the em-dash, condensed only as 9.4/9.5 require.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters in the file; the ER’s 🟩/🟥/🟨 tier markers and ⚠️ conflict flags were correctly dropped in favour of CSS and <strong> tier labels.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Tier lists collapsed to single semicolon-separated <li> items, gates to 9 and 10 short bullets, monitoring “Why” cells to single clauses; the print block pins A4 with 12 mm margins.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1 and before the template comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on line 3, closing --- on line 13; the “QRS — Metadata” caption on line 2 precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Wrapped in an HTML comment; no element repeats the raw metadata block.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly so because it contains a colon; all other values are bare and trimmed.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: r_lipoic_acid_2026-0810-0622_Opus_ER.md, matching the source ER’s own filename field (ER 17).
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the head of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0810-0745, correct YYYY-MMDD-HHMM form.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” = nickname + version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: r_lipoic_acid_2026-0810-0622_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all ten keys, including git_user: evipedia-2 and git_issue: 4991; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “R-Lipoic Acid for Health & Longevity - Quick Reference Sheet”; ER canonical_topic is “R-Lipoic Acid for Health & Longevity” (ER 8), with the ampersand correctly encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “R-Lipoic Acid for Health & Longevity”, exact match to ER canonical_topic with encoded ampersand.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/10/2026”, the correct MM/DD/YYYY rendering of qrs_creation_date: 2026-0810-0745.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the qrs_creator_ai_fullname frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the fixed subline; the ER’s long “Also known as” list (ER 30) is correctly absent.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses ER 584–586 into mechanism, the consistent-findings list, the responder qualifier, and the racemate caveat.
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“sulfur compound … energy compartments” and “brief chemical signal switching on the cell’s own protective machinery” ← ER 584; “Most consistent findings … abnormal” ← ER 586; “Nearly all testing used the blended form” ← ER 586.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “energy compartments” for mitochondria, “blended form” for racemate, “protective machinery” for Nrf2-driven antioxidant genes.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, or sample sizes appear.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect sizes or confidence intervals; only the qualitative “modest improvements”.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items map to the “Populations who should avoid this intervention” bullet (ER 419).
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete coverage: IAS history, HLA-DRB104:03/04:06, pregnancy and lactation, thiamine deficiency/alcohol use disorder, CKD stage 4+, ACR > 30 mg/g, prior autoimmune endocrine disease, children and adolescents, pre-surgical window.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Nine discrete <li> elements, lines 578–586.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No dashes or trailing clauses; the ER’s rationale (“given the platelet signal”, “on the grounds of absent safety data”) is stripped throughout.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Preserved: “stage 4 or worse (below 30 mL/min/1.73 m²)”, “above 30 mg/g”, “(approximately 30 mg/kg toxicity threshold)”, “Within two weeks of elective surgery”, and both HLA allele designations.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication bullet uses no ranking notation inside parentheses; its only “>”-style symbols are genuine numeric thresholds.
8.7	If no [stop_items] are present the section is left empty	N/A	Nine stop_items are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items map to the interaction bullets at ER 401–417.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All nine ER interaction bullets are represented (the “Additive supplement interactions” bullet correctly split into its glucose-lowering and blood-pressure/platelet halves); no overlap with the contraindication list.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Ten discrete <li> elements, lines 594–609.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s “— caution, dose adjustment required”, “— monitor”, “— caution, separate dosing”, and all Mitigation sentences are stripped; each item is a bare noun phrase.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Drug lists preserved for every item that has one: “(metformin, pioglitazone, SGLT2 inhibitors)”, “(levothyroxine, liothyronine)”, “(ibuprofen, naproxen, aspirin, antacids, proton pump inhibitors)”, “(warfarin, apixaban, clopidogrel)”, “(berberine, chromium picolinate, cinnamon, gymnema)”, “(fish oil, garlic, nattokinase)”, “(iron, copper, zinc, dimercaptosuccinic acid, penicillamine)”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	No ranking notation appears inside the parentheses of the ER’s interaction bullets.
9.7	If no [caution_items] are present the section is left empty	N/A	Ten caution_items are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Dose and timing come from ER 447, 453, 457; the ceiling from ER 445 (“Escalation to 1,200 or 1,800 mg/day adds adverse events without adding efficacy”), reinforced by ER 426.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, timing, and ceiling are the three decisions the ER’s protocol section turns on.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies well over three actionable aspects; all three sets are populated.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry substantive content; no placeholder text remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Nerve symptoms, insulin sensitivity, and body composition, all drawn from the “Time to effect” bullet at ER 502.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Nerve symptoms (High tier) first, then insulin sensitivity and body composition in the ER’s own Medium-tier order (ER 197, 203).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER names four time-to-effect domains; all three sets are populated.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Values “2–5 weeks”, “4–12 weeks”, “24 weeks” match ER 502; subs draw on ER 502 and ER 562.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides a dedicated “Time to effect” bullet (ER 502), so the subhead is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All 17 listed benefits correspond one-to-one with the ER sub-headings at ER 189–285.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at lines 545, 548, 554, 562, tiered as in the ER.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare ER sub-heading; no Magnitude figures (e.g. “-0.64 µU/mL”, “5.0% of body weight”) carried through.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits span.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items (1 high, 4 medium, 7 low, 5 speculative).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All 12 listed risks correspond one-to-one with the ER sub-headings at ER 313–381.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at lines 621, 624, 630, 635, tiered as in the ER.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare ER sub-heading; the ER’s Magnitude data (dose thresholds, case counts, allele frequencies) is fully stripped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks span; the ER’s “(Hirata’s disease)” gloss is correctly dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items (1 high, 4 medium, 3 low, 4 speculative).

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The table reproduces the ER’s biomarker table at ER 530–542.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 11 ER rows present, with targets and rationale verbatim: fasting insulin, HOMA-IR, fasting glucose, HbA1c, hs-CRP, fasting triglycerides, TSH and free T3, urine albumin-to-creatinine ratio, eGFR, complete blood count, ferritin and serum copper.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 798–803 reproduce the ER’s front-loaded cadence (ER 526, 528): baseline panel, glucose self-checks in weeks 1/2/4, 12-week and 24-week panels, then 6–12 monthly with quarterly kidney markers above 600 mg racemate.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All eight items map to the qualitative-marker bullets at ER 546–560.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All eight present with ER bold labels verbatim: neuropathic symptoms, energy and exercise tolerance, appetite and satiety, cognitive clarity, gastrointestinal tolerance, sleep quality and timing of any disturbance, skin, urine odour.

Issues 10/08/2026 08:09

Pass rate 100.00%. No issues found.

Issues 10/08/2026 08:05

1. 1.1 / 7.3 — At-a-glance inverts effect direction: at_a_glance (lines 436-437) reads “modest gains in insulin sensitivity, weight, body fat, and inflammation”, whereas the ER Conclusion (ER line 586) reports “modest improvements in insulin sensitivity, body weight, body fat, and inflammation markers” — “gains” states the opposite direction for weight, body fat, and inflammation.
2. 1.1 — Titration described as “standard”: action_3_sub (lines 485-486) asserts “Standard titration is half the target dose for the first two weeks”; the ER presents half-dose titration only as a risk-mitigation strategy (ER line 424) and never calls it standard.

Fixes 10/08/2026 08:05

1. 1.1 / 7.3 — At-a-glance effect direction: Changed “modest gains in insulin sensitivity, weight, body fat, and inflammation” to “modest improvements in …”, matching the ER Conclusion and restoring the correct direction of effect.
2. 1.1 — Titration no longer called “standard”: Changed action_3_sub from “Standard titration is half the target dose for the first two weeks.” to “Titration is half the target dose for the first two weeks.”

Issues 10/08/2026 07:56

1. 9.4 — Trailing clause kept as parenthetical: Line 609 renders the complementary-supplement interaction as “Acetyl-L-carnitine, N-acetylcysteine, glycine (beneficial additivity)”, carrying over the trailing clause of the ER’s bold label “Complementary supplement interactions — beneficial additivity”; every other caution item correctly strips its em-dash clause.

Fixes 10/08/2026 07:56

1. 9.4 — Trailing clause stripped from caution item: Changed the complementary-supplement caution item from “Acetyl-L-carnitine, N-acetylcysteine, glycine (beneficial additivity)” to “Acetyl-L-carnitine, N-acetylcysteine, glycine”, removing the trailing clause carried over from the ER’s em-dash label.

Issues 10/08/2026 07:51

1. 2.5 — Imperative dosing instruction: [action_3_sub] (QRS line 485) ends with “Start at half the target dose for two weeks.”, an imperative that advises rather than presents information.

Fixes 10/08/2026 07:51

1. 2.5 — Imperative dosing instruction: Rewrote the closing sentence of [action_3_sub] from “Start at half the target dose for two weeks.” to “Standard titration is half the target dose for the first two weeks.” so the cell states a fact rather than issuing an instruction.